tbuckley/cabot-search huggingface dataset:
STUDIES ON THE ETIOLOGY OF RABBIT POX
Authors: Louise Pearce, Paul D. Rosahn, Ch'uan-K'uei Hu
Journal: The Journal of Experimental Medicine (1936)

A filterable agent was isolated from 7 cases of spontaneous rabbit pox by the intratesticular injection in rabbits of a variety of tissues. The virus was transmitted for 15 consecutive testicle to testicle passages in rabbits by Berkefeld V filtrates of testicular tissue emulsions. Unfiltered emulsions were more potent than filtrates. The virulence of the virus was maintained by ice box storage of infected tissues for as long as 127 days. The pathogenic properties of the virus persisted under conditions of animal passage for the 9 months from January to October, 1933, covered by these studies. The reaction produced in rabbits by the inoculation of tissue-virus emulsions was of two principal types, the first of which has been described and analyzed in the present paper. In the case of intratesticular injections, particularly of testicular tissue inocula, an acute fulminating and rapidly fatal condition regularly developed. The outstanding features were a massive hemorrhagic orchitis with marked scrotal edema, fever, and death within a week. The second type of reaction which is taken up in the next paper of this series (1) was observed under conditions in which the animal survived a week or longer. Occasional examples occurred in rabbits of the so called intratesticular series. The reaction was characterized by the development of a disease syndrome with a diversity of clinical manifestations which, it may be stated here for the sake of continuity, was indistinguishable from spontaneous rabbit pox.
TCT-396 Percutaneous Coronary Interventions in Chronic Total Occlusions Performed by Radial Approach: A Multicentric Registry
Authors: Maria De Vita, Francesco Burzotta, Alessandro Iadanza, Trani Carlo, Mila Menozzi, Roberto Caporale, Francesco Tomassini, Gerardo Musuraca, Cristina Aurigemma, Susanna Benincasa, Marcello Galvani, Fabio Tarantino
Journal: Journal of the American College of Cardiology (2015)
Cough It Up
Authors: Lisa M. Bebell
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EGFR-TKI after disease progression with central nervous system metastasis in advanced non-small cell lung cancer with <i>EGFR</i> mutations.
Authors: Takashi Sone, Kazuo Kasahara, Koji Kurokawa, Asao Sakai, Toshiyuki Kita, Shingo Nishikawa, Kazuyoshi Watanabe, Hiroki Shirasaki, Taro Yoneda
Journal: Journal of Clinical Oncology (2013)

e19083 Background: Several retrospective studies have reported that continued treatment with EGFR-TKI after developing progressive disease (PD) by RECIST improved survival compared to TKI-free treatment in NSCLC patients with EGFR mutations. However, it is unclear which patients would benefit from EGFR-TKI after PD. We hypothesized that patients with CNS progression only, without systemic deterioration, would show a good prognosis with EGFR-TKI after PD. Methods: In order to clarify the survival benefits in patients treated by EGFR-TKI after developing PD, particularly patients with CNS metastasis alone, NSCLC patients with EGFR mutations who were treated with EGFR-TKI and showed progression were analyzed retrospectively. The patients were categorized into two groups: patients continuing with EGFR-TKI treatment after progression (continuation group) and patients switched to chemotherapy or BSC (discontinuation group). Patients were also classified into two groups by site of progression: patients who showed deterioration involving only CNS metastasis (CNS group) and patients who showed progression of the primary lesion, lymph nodes, bone, liver, adrenal glands, CNS, or other sites (systemic group). Differences in post-EGFR-TKI progression survival (PPS) and overall survival were compared between the groups. Results: A total of 75 patients, including 54 women, 56 never smokers, 73 patients with adenocarcinomas, and 57 patients with good PS (0, 1), were analyzed. There were 40 patients with deletions in exon 19, 29 patients with L858R, and 6 with minor mutations. The continuation group (n=36) had a significantly longer PPS than the discontinuation group (n=39) (16.2 m vs. 8.5 m, p&lt;0.01). Although it was not significant, the CNS group (n=14) showed longer PPS than the systemic group (n=61) (17.3 m vs. 9.2 m, p=0.10). The PPS of 9 patients (continuation and CNS groups) was 21.0 m, while PPS of 34 patients (discontinuation and systemic group) was 7.2 m. Conclusions: In this retrospective analysis, continued treatment with EGFR-TKI after PD resulted in longer PPS. A prospective study of patients with progression involving only CNS metastasis treated with EGFR-TKI is needed.
Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Authors: Peter Martin, Andre Goy, Radhakrishnan Ramchandren, Lucille Ferrante, Vijay Reddy, Anil Londhe, Mark Wildgust, Tracy McGowan, Nancy L Bartlett
Journal: Blood (2014)
Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations.
Authors: T. Safra, L. Borgato, M. Nicoletto, L. Rolnitzky, J. Curtin, R. Geva, S. Peles, T. Grenader, A. Gabizon, F. Muggia
Journal: Journal of Clinical Oncology (2010)

5043 Background: Does BRCA status affect outcome of rEOC patients treated with PLD? Tumors deficient in homologous recombination (HR) DNA repair are sensitive to platinums. Recurrences likely reflect acquired platinum resistance, perhaps from recovering BRCA function (as suggested in preclinical studies). We now investigate whether sensitivity to PLD and other DNA damaging agents is retained in BRCA mutation carriers (BRCA+) with rEOC. Methods: We retrospectively analyzed rEOC patients treated with PLD as second- or third-line from 1998 to 2009 in 4 institutions (Israel, Italy, NY):155 rEOC patients have been evaluated of which 38 (24.5%) are BRCA+ and 117 (75.5%) non-hereditary consisting of 35 (22.5%) who tested negative and 82 (53%) untested, (excluding 10 patients with a family history in a first-degree relative). Results: Median age is 59 (31-83) years; 44 (28%) patients have a platinum free interval (PFI) of < 6 months and 111 (72 %) of > 6 months; 104 (67%) received PLD as second-line and 55 (33%) as third-line. PLD with a platinum was used in 90 (58%) and PLD alone in 65 (42%). BRCA+ vs. non-hereditary comparisons show: response rate 68.4% vs. 49%; median TTF (time to failure) 11.4 (CI 95% 5.9-18.1) vs. 9.4 (CI 95% 7.7-11.9) m; OS (overall survival) 56.8 (CI 95% 32.5-87.9) vs. 22.6 (CI 95% 16.0-34.1) m this last comparison (p = 0.005). Cox survival models showed OS to be associated with BRCA status when adjusting for age and PFI (p = 0.02; hazard ratio, BRCA- vs. BRCA+ = 3.5); PFI was significantly associated with overall survival (p = 0.04). BRCA+are being further analyzed for role of subsequent platinums and other drugs. Conclusions: BRCA mutation carriers rEOC have improved outcome, suggesting persistent defects in HR, accounting for responses to other DNA damaging agents even after acquired platinum resistance. The potential role for PARP inhibitors after chemotherapy induced-remission is reinforced by these findings. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson Yissum-Hadasit Doxil Royalties
S77 Processing of Cigarette Graphic Health Warning Labels Decrease with Prolonged Exposure: Abstract S77 Table 1
Authors: C Ratneswaran, B Chisnall, MY Li, S Tan, A Devanand, J Steier
Journal: Thorax (2015)

<h3>Introduction</h3> Cigarette package graphic health warning labels (GHWL) remain an important means of communicating serious smoking risks. There were significant delays in implementing them in different countries around the world, partly due to tobacco company resistance; additionally, the messages used differ considerably. We expected a reduced cognitive processing of the messages based on the duration since launch. In order to address this question we compared a London (4 years) vs Singapore (8 years exposed) cohort. <h3>Methods</h3> We used a 50-item structured interview; after recording demographics and smoking history, 10 country-specific warning labels were shown. In addition to the emotional response and impact on smoking cessation/prevention, cognitive processing was assessed on a scale from ‘1’ (‘not at all/never’) to ‘5’ (‘all the time/a lot’). Smoking-risk knowledge and their importance in terms of prevention and treatment were elicited. <h3>Results</h3> 266 participants were recruited, 163 from London (52 ± 18 years, 54% male, 35% smokers) and 103 from Singapore (58 ± 15 years, p = 0.012; 78% male, p &lt; 0.001; 53% smokers, p = 0.003). Londoners read the labels more carefully and more often; they talked and thought more about them, even with no warning labels were in sight, and they kept packages more often as a reminder about their messages (overall, 2.0 ± 1.3 <i>vs</i> 1.5 ± 1.0, p &lt; 0.001). The processing differences between the cities were consistent when comparing the London and Singapore smokers (overall, 2.0 ± 1.1 <i>vs </i>1.6 ± 1.1, p &lt; 0.001) and non-smokers (overall, 2.0 ± 1.4 <i>vs </i>1.4 ± 0.8, p &lt; 0.001) (Table 1). Londoners experienced more disgust when viewing the images (79% <i>vs </i>53%, p &lt; 0.001) and felt they were more effective deterrents (51% <i>vs </i>35%, p = 0.011). One-in-five participants in Singapore were unaware of the association between smoking and lung cancer, despite it being the most deterring risk; blindness was the least well-known consequence in London (24%) and Singapore (34%, p = 0.075) despite being ranked ahead of stroke, oral cancer, and in smokers, ahead of heart disease for importance to prevent/treat. <h3>Conclusion</h3> A desensitisation to graphic health warning labels occurs with extended exposure. Non-smokers are prone to the same desensitisation as smokers are. In pre-empting this, the awareness and impact of specific health risks need to be actively utilised, in concerted public health campaigns, to help maintain label efficacy.
Biology Trumps Anatomic Location in Periampullary Cancers
Authors: Richard J. Bold
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Elevated 18F-FDG Uptake in Skeletal Muscles Rather Than Cutaneous Foci in a Patient With Sweet’s Syndrome
Authors: Shengming Deng, Bin Zhang, Xiuli Sui, Shibiao Sang, Wei Zhang
Journal: Clinical Nuclear Medicine (2016)

A 64-year-old man was admitted to our hospital with a history of recurrent fever lasting 2 months. The initial physical examination for the patient showed normal cutaneous signs. An elevated uptake of tracer in skeletal muscles was observed by F-FDG PET/CT imaging. Three weeks later, a multitude of painful erythematous maculopapules appeared over his face, chest, and back. Pathological examination of a skin lesion showed papillary dermal edema with predominantly dense neutrophilic infiltrate in the dermis with no evidence of vasculitis, which was consistent with Sweet's syndrome.
Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga–Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma
Authors: Arun Sasikumar, Ajith Joy, Raviteja Nanabala, Madhavan Unni, Padmanabhan TK
Journal: Clinical Nuclear Medicine (2016)

We describe a case of metastatic clear cell renal cell carcinoma with intensely tracer concentrating lesions in left suprarenal region, mediastinal lymph nodes, lytic bone lesions, thyroid nodules, and mild abnormal tracer-avid lung nodules in Ga-prostate-specific membrane antigen (PSMA) PET/CT. On the other hand F-FDG PET/CT showed mild to no significant abnormal uptake in these lesions. Complimentary uptake pattern was observed in Ga-PSMA and F-FDG PET images in thyroid lesions and D5 vertebral lesion. This case highlights the possibilities of imaging clear cell renal cell carcinoma with Ga-PSMA and opens the possibility of treatment with Lu-PSMA.
TCT-112 Prasugrel In Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE)- 3 Study
Authors: Renato Valenti, Vincenzo Comito, Rossella Marcucci, Marco Marrani, Giulia Cantini, Angela Migliorini, Guido Parodi, Benedetta Bellandi, Ruben Vergara, Gian Franco Gensini, Rosanna Abbate, David Antoniucci
Journal: Journal of the American College of Cardiology (2015)
A review of high grade non-Hodgkin lymphoma care in Ireland.
Authors: Rory Crotty, Maeve Crowley, Mary Cahill, Conleth G. Murphy, Jo O' Keeffe, Brian Richard Bird
Journal: Journal of Clinical Oncology (2014)

e17627 Background: High-grade non-Hodgkin lymphoma is an aggressive malignancy that requires urgent, intensive management. It is estimated that 60% of patients are cured (Cancer Research UK) so rapid diagnosis and commencement of chemotherapy are crucial to ensure the best possible outcomes. In Europe, there are very little data on how closely non-Hodgkin lymphoma management follows guidelines. This study is the first to address this issue in Ireland. Methods: The study was carried out in two hospitals affiliated with University College Cork. Ethical approval was obtained from the Cork Research Ethics Committee. 125 consecutive high-grade non-Hodgkin lymphoma patients were identified from the National Cancer Registry of Ireland. Appropriate quality markers were chosen (Wennekes et alia, J Clin Oncol 2011 April 10;29(11): 1436-1444.) and, in keeping with previous research, 90% adherence was set as the target. Data was obtained through a systematic retrospective chart analysis of paper and electronic records. Results: Analysis focused on three areas: diagnosis and staging, treatment, and organization of care. Diagnosis and staging markers were generally well adhered to. 92% of patients were diagnosed with an appropriate biopsy, and 98% of patients had appropriate blood tests performed. However, adherence rates for treatment and organization of care markers were much lower. 85% of patients received a DA-CHOP-R or DA-EPOCH-R regimen, and 75% of patients received a histological diagnosis within the 21 day target period. Chemotherapy was commenced within 28 days of diagnosis in 83% of patients. Adherence rates for the recording of standardized information were particularly low. 54% of patients had an International Prognostic Index score recorded. Use of the Cheson criteria to report treatment response was minimal. Overall, of 21 quality markers, 8 reached the target level. Conclusions: These results are in keeping with previously published studies. Irish hospitals are meeting management guidelines in 8 of 21 areas. Although guideline adherence rates are similar to international data, much more needs to be done to achieve optimal standards of care. Given that some criteria are rarely applied, there is a question about their practicality in clinical practice.
On CDC’s 70th Anniversary, Director Tom Frieden, MD, Looks Ahead
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surveillance for Silicosis — Michigan and New Jersey, 2003–2011
Authors: Patricia L. Schleiff, Jacek M. Mazurek, Mary Jo Reilly, Kenneth D. Rosenman, Martha B. Yoder, Margaret E. Lumia, Karen Worthington
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

CDC's National Institute for Occupational Safety and Health (NIOSH), state health departments, and other state entities maintain a state-based surveillance program of confirmed silicosis cases. Data on confirmed cases are collected and compiled by state entities and submitted to CDC. This report summarizes information for cases of silicosis that were reported to CDC for 2003-2011 by Michigan and New Jersey, the only states that continue to provide data voluntarily to NIOSH. The data for this report were final as of January 8, 2015. Data are presented in tabular form on the number and distribution of cases of silicosis by year (Table 1), duration of employment in occupations with potential exposure to dust containing respirable crystalline silica (Table 2), industry (Table 3), and occupation (Table 4). The number of cases by year is presented graphically (Figure). This report is a part of the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, which encompasses various surveillance years but is being published in 2016 (1). The Summary of Notifiable Noninfectious Conditions and Disease Outbreaks appears in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases (2).
Association of Indoor Tanning Frequency With Risky Sun Protection Practices and Skin Cancer Screening
Authors: Alexander H. Fischer, Timothy S. Wang, Gayane Yenokyan, Sewon Kang, Anna L. Chien
Journal: JAMA Dermatology (2016)

Indoor tanning is prevalent among young adults and women and is associated with increased risk of melanoma. Evidence suggests that indoor tanners may be more inclined to adopt poor photoprotective practices that further increase their risk of skin cancer; however, gaps in the literature exist in young adults and by indoor tanning frequency.To examine the association between indoor tanning frequency and behaviors related to skin cancer prevention and to investigate whether these associations vary by age group or sex.Cross-sectional population-based study of US 2015 National Health Interview Survey data including 10 262 non-Hispanic white adults aged 18 to 60 years without a history of skin cancer.Rare/never use of sunscreen, protective clothing, shade; multiple sunburns within the past year; previous full-body skin examination.Of the 10 262 individuals in our study population (49% female; median age, 39 y), 787 (7.0%) reported having tanned indoors in the past year. Among individuals aged 18 to 34 years, frequent indoor tanners (≥10 times in the past year) were more likely to report never/rare use of protective clothing (adjusted prevalence ratio [aPR], 1.28; 95% CI, 1.10-1.49) and shade (aPR, 1.32; 95% CI, 1.03-1.70), compared with individuals who did not tan indoors. Among women aged 18 to 60 years, those who frequently tanned indoors were more likely to rarely/never use sunscreen (aPR, 1.34; 95% CI, 1.11-1.62), protective clothing (aPR, 1.27; 95% CI, 1.15-1.42), and shade (aPR, 1.54; 95% CI, 1.25-1.90) on a warm sunny day, as well as more likely to report multiple sunburns in the past year (aPR, 1.21; 95% CI, 1.00-1.45) compared with those who did not tan indoors. Individuals who tanned indoors in the past year were not significantly more likely to have undergone a previous full-body skin examination in any subpopulation examined.Individuals who tan indoors often exhibited a concurrent tendency to sunburn, avoid sun protection, and avoid skin cancer screening. Thus, the findings highlight that in addition to tanning bed avoidance, it is critical to emphasize sun protection and skin cancer screening in individuals who tan indoors.
Epidermoid cyst within an intrapancreatic accessory spleen: endosonography and confocal endomicroscopy of an unusual pancreatic cystic lesion
Authors: Rohan Modi, Amrit Kamboj, Benjamin Swanson, Darwin Conwell, Somashekar Krishna
Journal: Endoscopy (2016)

A 62-year-old man with a history of a cholecystectomy presented with longstanding right upper quadrant pain. A computed tomography (CT) scan demonstrated a normal spleen with incidental small adjacent splenules and a 2.4 × 2.3-cm cystic lesion in the tail of the pancreas. The pancreatic cystic lesion (PCL) had not been seen on a CT scan 2 years earlier, while an interim CT scan had revealed a lesion of 1.1 × 1.1 cm.
Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project.
Authors: Maria Alma Rodriguez, Myron S. Czuczman, Jonathan W. Friedberg, Michelle E. Kho, Ann S. LaCasce, Michael Millenson, Nademanee Auayporn, Joyce Niland, Anna Ter Veer, Andrew D. Zelenetz, Jane C. Weeks
Journal: Blood (2005)
GW27-e1093 Percutaneous left atrial appendage closure in patients with non-valvular atrial fibrillation: a single center experience
Authors: Li Huakang, Yao Qing, Shu Maoqing, Zhong Li, Guo Yanli, Shen Bing, Huang Haiyun, Wang Wenting, Song Zhiyuan
Journal: Journal of the American College of Cardiology (2016)